In cancer cells, the two major outcomes of the RIG-I signalling pathway are type I IFNs production and preferential activation of programmed tumour apoptosis [48], with features of immunogenic cell death (ICD) [49,50,51]. This evidence concerns the gene RIGI and cancer.